Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day
RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Dr. Sandy Macrae, Sangamo's chief executive officer, will provide a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27th at 2:30 p.m. Eastern Time. The meeting is being held in Boston, MA.
The presentation and discussion will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investor Relations section under Events and Presentation. A live video webcast of the presentation will also be available at http://www.arminvestorday.com/webcast. The presentation will be archived on the Sangamo website for two weeks once the replay of the event is available.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-participation-in-the-arm-5th-annual-cell--gene-therapy-investor-day-300444504.html
SOURCE Sangamo Therapeutics, Inc.
Released April 24, 2017